Alfred Scheidegger | Founder and Partner
Nextech Invest | Switzerland

Alfred Scheidegger, Founder and Partner, Nextech Invest

Before founding Nextech Invest Ltd. in 1998, Scheidegger was managing director and member of the board of the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. Earlier he served as the first managing director of the Swiss Supercomputing Center (CSCS), and lead an international drug-discovery project at Ciba-Geigy (today Novartis), Japan. He is co-initiator of Venture 98, the first Swiss national business plan contest. Scheidegger holds a PhD in biochemistry and microbiology from the University of Basel, Switzerland, has completed a post-doctorate research fellowship in enzymology at the University of Kyoto, Japan, and an executive training program at Harvard Business School, USA. He has over 15 years of investment experience in the biotechnology industry.
Currently, Alfred Scheidegger is on the board of directors at Cleave Biosciences, Molecular MD (observer), Dottikon ES Holding and Rising Tide Foundation. Past board representations include Agensys (acquired by Astellas), Ganymed Pharmaceuticals (acquired by ATS, later Astellas), MacroGenics (NASDAQ: MGNX), Sunesis Pharmaceuticals (NASDAQ: SNSS), Tetralogic Pharmaceuticals (NASDAQ: TLOG), and Tracon Pharma (NASDAQ: TCON).


Phar-East Day One @ 08:50

Chair's Opening Remarks

Phar-East Day One @ 09:40

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?

Phar-East Day Two @ 13:25

How to Capture Value in a Fast-Paced, Disruptive Industry

back to speakers